Amram, O. et al., “
Changes in Methadone Take-Home Dosing Before and After COVID-19,”
Journal of Substance Abuse Treatment 133 (
2022): 108552, doi:
10.1016/j.jsat.2021.108552; M. C. Figgatt et al., “Take-Home Dosing Experiences Among Persons Receiving Methadone Maintenance Treatment During COVID-19,”
Journal of Substance Abuse Treatment 123 (2021): 108276, doi:
10.1016/j.jsat.2021.108276; L. W. Suen et al., “’The Idea is to Help People Achieve Greater Success and Liberty’: A Qualitative Study of Expanded Methadone Take-Home Access in Opioid Use Disorder Treatment,”
Substance Abuse 43, no. 1 (2022): 1143-1150, doi:
10.1080/08897077.2022.2060438; S. M. Walters et al., “Lessons from the First Wave of COVID-19 for Improved Medications for Opioid Use Disorder (MOUD) Treatment: Benefits of Easier Access, Extended Take Homes, and New Delivery Modalities,”
Substance Use & Misuse 57, no. 7 (2022): 1144-1153, doi:
10.1080/10826084.2022.2064509; O. Amram et al., “The Impact of Relaxation of Methadone Take-Home Protocols on Treatment Outcomes In The COVID-19 Era,”
American Journal of Drug & Alcohol Abuse 20 (2021): 1-8, doi:
10.1080/00952990.2021.1979991; S. Brothers, A. Viera, and R. Heimer, “Changes in Methadone Program Practices and Fatal Methadone Overdose Rates in Connecticut During COVID-19,”
Journal of Substance Abuse Treatment 131 (2021): 108449, doi:
10.1016/j.jsat.2021.108449; X. A. Levander, et al., “Rural Opioid Treatment Program Patient Perspectives on Take-Home Methadone Policy Changes During COVID-19: A Qualitative Thematic Analysis,”
Addiction Science & Clinical Practice 16, no. 1 (2021): 72, doi:
10.1186/s13722-021-00281-3.
CrossRefGoogle ScholarPubMed